MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Corcept Therapeutics, Inc. (CORT) Partners With Idis To Provide Worldwide Access To Korlym 0 comments
    Jul 25, 2013 3:12 PM | about stocks: CORT

    Pharmaceutical company Corcept Therapeutics has announced that its Korlym (mifepristone) 300 mg tablets are available to patients outside the U.S. through an Idis Access Program.

    Through a regulatory-compliant and ethical channel on a named-patient basis, Idis Access Programs enable patients worldwide to be prescribed investigational or approved drugs prior to their commercial launch in the patient's country.

    Since April 2012, Corcept has been offering Korlym in the U.S. as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with type 2 diabetes or glucose intolerance who have failed surgery or are not candidates for surgery.

    "We are pleased to partner with Idis so that physicians outside the United States can prescribe Korlym," said Corcept Vice President of Commercial Operations Steven Lo. "We are dedicated to meeting the needs of patients worldwide. Our partnership with Idis will help us make sure that every Cushing's syndrome patient who could benefit from Korlym will have access to the medicine."

    Interested licensed healthcare professionals outside the U.S. who have patients that might benefit from Korlym can contact Idis directly for more information.

    For more information, visit www.corcept.com

    Please see disclaimer on the MissionIR website

    Stocks: CORT
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.